According to the NSCLC CSCO 2022 guideline, detection of SNV/indel of EGFR, KRAS, HER2 and BRAF genes, CNV of MET and HER2, gene fusions of ALK, ROS1, RET and NTRK, and MET exon 14 skipping (METΔex14) would facilitate clinical application of target drugs for NSCLC patients based on these gene variations. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.